A5089395073- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Immunodeficiency and Autoimmune Disorders
- Histone Deacetylase Inhibitors Research
- Retinoids in leukemia and cellular processes
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Genomic variations and chromosomal abnormalities
- Epigenetics and DNA Methylation
- Glycosylation and Glycoproteins Research
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- MicroRNA in disease regulation
- Cancer-related Molecular Pathways
- RNA Interference and Gene Delivery
- Advanced Breast Cancer Therapies
- Immune Cell Function and Interaction
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
University Hospital Ulm
2016-2025
Medizinische Hochschule Hannover
2002-2024
Universität Ulm
2014-2023
Epigenomics (Germany)
2012-2023
German Cancer Research Center
2003-2023
Heidelberg University
2004-2023
University Hospital Heidelberg
1993-2023
University of Augsburg
2023
Helmholtz-Institute Ulm
2020-2021
Kent and Canterbury Hospital
2020
Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology AML and informs clinical practice.
Fluorescence in situ hybridization has improved the detection of genomic aberrations chronic lymphocytic leukemia. We used this method to identify chromosomal abnormalities patients with leukemia and assessed their prognostic implications.Mononuclear cells from blood 325 were analyzed by fluorescence for deletions chromosome bands 6q21, 11q22-23, 13q14, 17p13; trisomy 3q26, 8q24, 12q13; translocations involving band 14q32. Molecular cytogenetic data correlated clinical findings.Chromosomal...
Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in previous phase 1b study.
Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients standard chemotherapy would prolong overall survival this population.We screened 3277 patients, 18 59 years age, who had newly diagnosed AML for mutations. were randomly assigned receive (induction therapy daunorubicin cytarabine consolidation high-dose cytarabine)...
Abstract The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis management acute myeloid leukemia (AML) in adults are widely recognized among physicians investigators. There have been major advances our understanding AML, including new knowledge about molecular pathogenesis leading to an update disease classification, technological progress genomic diagnostics assessment measurable residual disease, successful development therapeutic agents, such as FLT3,...
Mutations occur in several genes cytogenetically normal acute myeloid leukemia (AML) cells: the nucleophosmin gene (NPM1), fms-related tyrosine kinase 3 (FLT3), CCAAT/enhancer binding protein α (CEPBA), myeloid–lymphoid or mixed-lineage (MLL), and neuroblastoma RAS viral oncogene homolog (NRAS). We evaluated associations of these mutations with clinical outcomes patients.
All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies treatment arsenic trioxide or without ATRA have shown high efficacy and reduced hematologic toxicity.We conducted a phase 3, multicenter trial comparing plus patients APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either induction consolidation...
The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients previously untreated chronic lymphocytic leukemia (CLL) but not those coexisting conditions. We investigated the benefit of type 2, glycoengineered obinutuzumab (also known as GA101) compared that each chlorambucil, CLL and conditions.We randomly assigned 781 a score higher than 6 on Cumulative Illness Rating Scale (CIRS) (range, 0 56,...
Comparative genomic hybridization (CGH) to metaphase chromosomes has been widely used for the genome-wide screening of imbalances in tumor cells. Substitution chromosome targets by a matrix consisting an ordered set defined nucleic acid target sequences would greatly enhance resolution and simplify analysis procedure, both which are prerequisites broad application CGH as diagnostic tool. However, whole human DNA immobilized single-copy fragments with complexities below megabase pair level...
In patients with acute myeloid leukemia (AML), the presence or absence of recurrent cytogenetic aberrations is used to identify appropriate therapy. However, current classification system does not fully reflect molecular heterogeneity disease, and treatment stratification difficult, especially for intermediate-risk AML a normal karyotype.